Követés
Vidhi Khanna
Vidhi Khanna
Biocon-Bristol Myers Squibb Research Centre (BBRC), Bangalore
Nincs ellenőrzött e-mail-cím
Cím
Hivatkozott rá
Hivatkozott rá
Év
Discovery of HSPG2 (Perlecan) as a therapeutic target in triple negative breast cancer
S Kalscheuer, V Khanna, H Kim, S Li, D Sachdev, A DeCarlo, D Yang, ...
Scientific reports 9 (1), 1-11, 2019
352019
Combination of sunitinib and PD-L1 blockade enhances anticancer efficacy of TLR7/8 agonist-based nanovaccine
H Kim, V Khanna, TA Kucaba, W Zhang, DM Ferguson, TS Griffith, ...
Molecular pharmaceutics 16 (3), 1200-1210, 2019
342019
Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer
V Khanna, S Kalscheuer, A Kirtane, W Zhang, J Panyam
Future drug discovery 1 (1), FDD8, 2019
332019
TLR7/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy
H Kim, V Khanna, TA Kucaba, W Zhang, D Sehgal, DM Ferguson, ...
Molecular pharmaceutics 17 (6), 2109-2124, 2020
302020
Fibrinolytic enzyme cotherapy improves tumor perfusion and therapeutic efficacy of anticancer nanomedicine
AR Kirtane, T Sadhukha, H Kim, V Khanna, B Koniar, J Panyam
Cancer research 77 (6), 1465-1475, 2017
302017
Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
V Khanna, H Kim, W Zhang, P Larson, M Shah, TS Griffith, D Ferguson, ...
Scientific reports 11 (1), 1-13, 2021
202021
Chemopreventive efficacy of oral curcumin: a prodrug hypothesis
G Liu, V Khanna, A Kirtane, A Grill, J Panyam
The FASEB Journal 33 (8), 9453-9465, 2019
92019
Exploiting antibody biology for the treatment of cancer
V Khanna, J Panyam, TS Griffith
Immunotherapy 12 (4), 255-267, 2020
72020
Therapeutic efficacy of antibodies targeting domain 1 of HSPG2 in breast cancer
V Khanna, S Kalscheuer, J Panyam, D Yang, S Li
Cancer Research 78 (13 Supplement), 2897-2897, 2018
12018
Chitosan: A Biopolymer for Skin Regeneration
M Khakharia, V Khanna
The Bombay Technologist 62, 1-10, 2013
12013
Antibody fragments for detecting cancer and methods of use
J Panyam, S Kalscheuer, VD Khanna
US Patent App. 16/745,153, 2020
2020
TLR agonists for anticancer immunotherapy
W Zhang, H Kim, V Khanna, DM Ferguson, T Griffith, J Panyam
Cancer Research 79 (13 Supplement), 4985-4985, 2019
2019
Novel small molecule TLR7/8 agonists for enhancing NK cell-mediated ADCC
V Khanna, H Kim, W Zhang, P Larson, D Ferguson, J Panyam
Cancer Research 79 (13 Supplement), 4129-4129, 2019
2019
Antibodies in Cancer Therapy: New Targets, Applications and Combination Strategies
VD Khanna
2019
Antibody Conjugated Nanoparticles for Targeting Metastatic Triple Negative Breast Cancer
VD Khanna
2016
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–15